BridgeMD
New treatment option for Ischemic Stroke
Official title Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in China
ClinicalTrials.gov ID: NCT07143149
What this study is testing
- What it's testing
- This study will conduct a cluster randomized controlled trial to Evaluate whether the Intelligent Lipid Management Decision-support System can increase the proportion of patients 1-year target achievement (\<1.8 mmol/L) in acute ischemic stroke or TIA patients under Evolocumab treatment within 12 months post-intervention.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age≥18 years as of the screening date;
- Patients with non-cardioembolic ischemic stroke or TIA within 3 months prior to the screening date;
- Prescribed Evolocumab at physician's discretion;
- Signed informed consent.
You likely can't join if
- Intracranial hemorrhagic diseases: such as cerebral hemorrhage, subarachnoid hemorrhage, etc.;
- Patients confirmed by baseline head CT or MRI to have hemorrhage or other pathological brain diseases, such as vascular malformations, tumors...
- Silent cerebral infarction without signs and symptoms;
- Participation in a clinical trial of another drug or device in the past 3 months or ongoing at the time of the screening date;
- Any prior use of Evolocumab or other PCSK9 inhibitor treatments within the past 6 months prior to the screening date;
- Life expectancy \<12 months or unable to complete the research for other reasons as of the screening date;
See the full eligibility criteria
- Age≥18 years as of the screening date;
- Patients with non-cardioembolic ischemic stroke or TIA within 3 months prior to the screening date;
- Prescribed Evolocumab at physician's discretion;
- Signed informed consent.
- Intracranial hemorrhagic diseases: such as cerebral hemorrhage, subarachnoid hemorrhage, etc.;
- Patients confirmed by baseline head CT or MRI to have hemorrhage or other pathological brain diseases, such as vascular malformations, tumors, abscesses, or other common non-ischemic brain diseases (such as multiple...
- Silent cerebral infarction without signs and symptoms;
- Participation in a clinical trial of another drug or device in the past 3 months or ongoing at the time of the screening date;
- Any prior use of Evolocumab or other PCSK9 inhibitor treatments within the past 6 months prior to the screening date;
- Life expectancy \<12 months or unable to complete the research for other reasons as of the screening date;
- Inability to understand and/or follow research procedures due to mental, cognitive, or emotional disorders;
- Refusal to participate in the enrollment survey.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, China
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.